Jpmorgan Chase & CO Vyne Therapeutics Inc. Call Options Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding VYNE

# of Institutions
2
Shares Held
36.5K
Call Options Held
0
Put Options Held
0
View Full List

About VYNE Therapeutics Inc.

VYNE Quotes by TradingView
  • Ticker VYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,005,600
  • Market Cap $184M
  • Description
  • VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...
More about VYNE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email